Accueil>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>PI4KIIIbeta-IN-9

PI4KIIIbeta-IN-9

Catalog No.GC32847

PI4KIIIbeta-IN-9 est un puissant inhibiteur de PI4KIIIβ avec une IC50 de 7 nM. PI4KIIIbeta-IN-9 inhibe également PI3Kδ et PI3Kγ avec des IC50 de 152 nM et 1046 nM, respectivement.

Products are for research use only. Not for human use. We do not sell to patients.

PI4KIIIbeta-IN-9 Chemical Structure

Cas No.: 1429624-84-9

Taille Prix Stock Qté
10mM (in 1mL DMSO)
446,00 $US
En stock
1mg
83,00 $US
En stock
5mg
264,00 $US
En stock
10mg
446,00 $US
En stock
25mg
970,00 $US
En stock
50mg
1 586,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.

PI4KIIIbeta-IN-9 (Compound 9) shows weak inhibition of PI3KC2γ (IC50 ~1 µM), PI3Kα (~2 µM), and PI4KIIIα (~2.6 µM) and <50% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ. PI4KIIIbeta-IN-9 (Compound 9) forms a crescent shape that conforms to the active site of PI4KIIIβ. This molecule makes extensive contacts with PI4KIIIβ[1].

[1]. Rutaganira FU, et al. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. J Med Chem. 2016 Mar 10;59(5):1830-9.

Avis

Review for PI4KIIIbeta-IN-9

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PI4KIIIbeta-IN-9

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.